Effect of Low-Dose Oral Etoposide on Serum CA-125 in Patients with Advanced Epithelial Ovarian Cancer
- 1 August 1997
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 66 (2) , 197-201
- https://doi.org/10.1006/gyno.1997.4760
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?Cancer, 1996
- CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990sAmerican Journal of Obstetrics and Gynecology, 1996
- Tumor markers in the management of patients with ovarian cancerCancer Treatment Reviews, 1995
- Second‐line chemotherapy for recurrent carcinoma of the ovaryCancer, 1993
- Taxol in ovarian cancerCancer, 1993
- Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.Journal of Clinical Oncology, 1992
- CA-125 in ovarian cancer: Relation between half-life, doubling time and survivalEuropean Journal of Cancer and Clinical Oncology, 1991
- CA 125 regression: A model for epithelial ovarian cancer responseAmerican Journal of Obstetrics and Gynecology, 1991
- Does intraperitoneal CA-125 reflect disease status?Gynecologic Oncology, 1991
- Reporting results of cancer treatmentCancer, 1981